stockrow4D Molecular Therapeutics, Inc. (FDMT) vs Zevra Therapeutics, Inc. (ZVRA)
- 4D Molecular Therapeutics, Inc. FDMT 12.32 +9.51%
- Zevra Therapeutics, Inc. ZVRA 11.55 +9.69%
4D Molecular Therapeutics, Inc. and Zevra Therapeutics, Inc. are both Biotechnology companies. 4D Molecular Therapeutics, Inc. and Zevra Therapeutics, Inc. are of similar size ($626.6M and $621.5M). 4D Molecular Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Zevra Therapeutics, Inc. trades at 9.0×. 4D Molecular Therapeutics, Inc. grew revenue faster over the last twelve months: 278,712.1% against 75.1%. Zevra Therapeutics, Inc. has the higher net margin (50.7% vs −194.7%) and the higher return on invested capital (129.5% vs −186.9%). Across the 18 metrics below, Zevra Therapeutics, Inc. leads on 13 and 4D Molecular Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | FDMT | ZVRA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 95.44% | 68.51% |
| Operating margin | (214.24%) | 60.78% | 0.00% |
| Net margin | (194.74%) | 50.73% | 0.00% |
| Free cash flow margin | (169.51%) | 58.93% | 0.00% |
| Return on equity | (43.25%) | 40.29% | (51.96%) |
| Return on assets | (37.09%) | 25.69% | (46.06%) |
| Return on invested capital | (186.91%) | 129.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack